This page lists past opportunities from CIP.
Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.
Guoying Liu, Ph.D. (email@example.com)
The National Cancer Institute (NCI) is announcing the availability of administrative supplemental funds for NCI-funded cancer center grantees (P30s) (domestic only). The primary purpose of this initiative is to provide matching funds to assist in the acquisition of dedicated clinical research imaging equipment, or significant upgrades to existing clinical research imaging equipment (software and/or hardware), in order to optimize the use of imaging as a biomarker in Phase 1 and 2 oncologic trials. The initiative is part of a continuing effort to stimulate and strengthen the use of imaging techniques in cancer research. NCI-funded cancer centers possess the infrastructure, organization, leadership, and integrated multidisciplinary research objectives that enable them to build and incorporate new image technologies into cancer clinical trials.
See full description in NIH Guide:NOT-CA 03-026
Barbara Y. Croft, Ph.D. (firstname.lastname@example.org) at 301-496-9531
The National Cancer Institute (NCI) is announcing the availability of administrative supplemental funds for NCI-funded R24, P30, P50, U01, and U54 grantees (domestic only). This administrative supplemental initiative is intended to assist the grantees in creating or extending capabilities in small animal imaging. The initiative is part of a continuing effort to stimulate and strengthen research in small animal imaging techniques and to increase the use of small animal imaging techniques in cancer research. The Instrumentation Grants For Small Animal Imaging Equipment (Administrative Supplements) will provide dedicated funds to buy or upgrade imaging equipment for small animals, emphasizing those modalities that can provide biochemical, molecular, genetic or pharmacological information in vivo.
See full description in NIH Guide:NOT-CA 03-016
Barbara A. Galen, M.S.N., C.R.N.P. (email@example.com)
The NCI is requesting competing renewal applications from the American College of Radiology Imaging Network (ACRIN), funded originally through RFA CA-97-020. This will continue a unique ongoing project at its current level and scope to best serve the oncology and imaging science communities. This is particularly important now because ACRIN is currently conducting several ongoing imaging clinical trials critical to the goals of the NCI. The combination of imaging with minimally invasive diagnosis and treatment will enhance clinical practice by limiting disfigurement, trauma and expense.
See full description in NIH Guide:NCI NOT-CA-03-001
The Cancer Imaging Program (CIP), Division of Cancer Diagnosis and Treatment (DCTD), National Cancer Institute (NCI) plans to develop contracts to support Phase 1 (Safety) and Phase 2 (Preliminary Clinical Efficacy) clinical trials of promising imaging agents. These clinical trials will be used to rapidly evaluate the safety and diagnostic imaging capabilities of promising imaging probes, ligands, radiopharmaceuticals, and contrast agents that are of interest to NCI. The Safety and Preliminary Clinical Efficacy Imaging Clinical Trials contracts will create an infrastructure poised to rapidly evaluate molecularly-targeted imaging agents used to assess therapeutic anticancer agents on their molecular targets and determine clinically relevant correlates. The objectives of this program are: to rapidly conduct clinical trials necessary to assess the safety of promising imaging agents; to rapidly conduct clinical trials necessary to assess the diagnostic imaging capabilities and preliminary efficacy of promising imaging agent to characterize the molecular interactions of new molecular imaging agents with their targets through biopsies, assays, and other appropriate technologies and correlate those effects with clinically-relevant endpoints; to develop new scientific insights into molecular pathways and determinants of the relationship of the targeted imaging agents to therapeutic drug response. Major emphasis shall be on imaging agents which are found to be safe and provide important structural, metabolic, or molecular imaging data which will be important and useful in the management of patients with cancer. These Phase 1 and Phase 2 clinical trials will obtain the necessary data to fulfill the Food and Drug Administration (FDA) criteria to eventually become an approved and potentially marketable imaging agent for specific imaging indications. The studies will explore promising imaging agents, and require rapid initiation, completion, and data reporting. These contracts will also require the ability to implement correlative studies validating the localization of the investigational imaging agents on their molecular target in tumors. Imaging agents may originate from investigators not affiliated with clinical sites. The Government anticipates that five (5) contracts will be awarded on an incrementally funded basis for five years. The size of each trial might vary depending on consultation with the FDA for each specific agent. The typical size for each Safety trail will be approximately 10 patients. The typical size for each Preliminary Clinical Efficacy trail is estimated to be 25 patients. NAICS Code No. 621512 with a size standard of $5.Million.
See full description:RFP: N01-CM-37008
The Cancer Imaging Program (CIP), of the Division of Cancer Treatment and Diagnosis (DCTD) solicits applications for cooperative agreement (U54) awards to establish a Specialized Research Resource Center that will participate as a member of a network of inter-disciplinary, inter- institutional research teams for the purpose of supporting translational research in optical imaging and/or spectroscopy in vivo. The network will operate under the guidance of a Steering Committee (SC). The goal is to organize a consortium with flexibility in scope, funding, and incentives to encourage inter- and intra-team collaborations on translational cancer research. The objective is to accelerate the pace of translational research by developing a consensus process to improve methods for system integration, optimization and validation of next-generation in vivo optical imaging and/or spectroscopy methods and technologies, including contrast agents. The research scope includes feasibility studies for the detection of pre-cancerous lesions, cancer detection and diagnosis, and measurement or prediction of response to therapy.
See full description in NIH Guide:RFA: CA-03-002
The National Cancer Institute (NCI) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) invite applications to develop novel in vivo image acquisition or enhancement methods, and incorporate limited pilot or feasibility evaluations using either pre-clinical models or clinical studies. This initiative is intended to facilitate the development of novel imaging technologies for early detection, screening, diagnosis, and image guided treatment of cancer and other diseases. The intent is to stimulate (a) the development of innovative image acquisition and enhancement methods, including high risk/high gain research on technologies that exploit our knowledge of the molecular basis of cancer or other disease, and (b) the integration of these emerging technologies with traditional imaging methods for more effective solutions for health care delivery. A phased innovation award mechanism (R21/R33) is proposed that is suitable for supporting imaging technology development. Applications from academia, industry, and independent research organizations are encouraged. Modifications to this reissued Program Announcement include support for a limited number of system prototypes for pilot or feasibility evaluations using either pre-clinical models or clinical studies. Applicants considering developments for ex vivo or in vitro molecular imaging are encouraged to read announcements PAR-01-105 and PAR-01-107 for Innovative Technologies for the Molecular Analysis of Cancer, listed under NCI Initiatives. Small business applicants with in vivo imaging interests are encouraged to apply under announcement, PAR-01-102.
See full description in NIH Guide:PAR-01-101
Anne E. Menkens, Ph.D. (firstname.lastname@example.org) at 301-435-9024
The Biomedical Imaging Program (CIP), of the Division of Cancer Treatment and Diagnosis (DCTD) solicits exploratory/developmental (R21) grants that articulate highly innovative research concepts in diagnostic cancer imaging. Within each area of importance in imaging, there exists a need for innovative and creative approaches leading to new avenues of research. One way to encourage research into high risk/high impact areas is to provide investigators with the initial resources required to accomplish feasibility and pilot testing of innovative ideas. The R21 mechanism will provide investigators at all career levels with a defined level of funding adequate for the initial feasibility testing of high risk/high impact concepts and, if the concepts are viable, for the generation of experimental preliminary data. This would render the investigators competitive for continued funding through other NIH research award mechanisms, thus potentially leading to the establishment of new research programs in areas that might have previously remained unexplored.
See full description in NIH Guide:PA-01-030
Barbara Y. Croft, Ph.D. (email@example.com) at 301-496-9531
Support both: (a) inter-disciplinary shared imaging research resources to be used by cancer investigators and (b) research related to small animal imaging technology.
See full description in NIH Guide:NCI/CIP RFA: CA-01-012
Grants are designed to support inter-disciplinary centers for functional imaging research (imaging sciences, chemistry, radiopharmaceutical chemistry, cell and molecular biology, pharmacology, computer science and biomedical engineering).
See full description in NIH Guide:RFA: CA-01-010
The National Cancer Institute (NCI) invites applications on the development of novel image acquisition or enhancement methods, incorporating limited pilot or feasibility evaluations using either pre-clinical models or clinical studies. This initiative is intended to facilitate the development of novel imaging technologies for early detection, screening, diagnosis and image guided treatment of cancer and other diseases. The intent is to stimulate: (a) the development of highly innovative image acquisition and enhancement methods, including high risk/high gain research on technologies that exploit our knowledge of the molecular basis of cancer or other disease, and (b) the integration of these emerging technologies with traditional imaging methods for more effective solutions for health care delivery. A phased innovation award mechanism (R21/R33) is proposed that is more suitable for supporting imaging technology development. Applications from academia, industry and the use of the SBIR/STTR funding mechanisms are encouraged.
See full description in NIH Guide:PAR-00-090